Wide Ranks

IONS

Ionis Pharmaceuticals, Inc.

35.90

Top Statistics
Market Cap 5 B Forward PE -13.96 Revenue Growth -7.20 %
Current Ratio 8.91 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -44.68 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -15.38 Enterprise / Revenue 6.44 Price To Sales Trailing12 Months 7.06
Profitability
Profit Margins -44.68 % Operating Margins -111.09 %
Balance Sheet
Total Cash 2 B Total Cash Per Share 15.78 Total Debt 1 B
Total Debt To Equity 301.12 Current Ratio 8.91 Book Value Per Share 4.20
All Measures
Short Ratio 913.00 % Message Board Id finmb_30300 Shares Short Prior Month 9 M
Return On Equity -0.7338 City Carlsbad Uuid e2f8b663-1b31-3cee-8363-06c9dcf00fd4
Previous Close 35.37 First Trade Date Epoch Utc 674 M Book Value 4.20
Beta 0.3920 Total Debt 1 B Volume 923689
Price To Book 8.55 Fifty Two Week Low 33.33 Total Cash Per Share 15.78
Total Revenue 803 M Shares Short Previous Month Date 1 B Target Median Price 62.00
Max Age 86400 Recommendation Mean 1.84 Sand P52 Week Change 0.3133
Operating Margins -111.09 % Target Mean Price 61.36 Net Income To Common -358811008
Short Percent Of Float 0.0817 Implied Shares Outstanding 157 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 2 B Next Fiscal Year End 1 B Revenue Per Share 5.50
Held Percent Insiders 0.0076 Ebitda Margins -41.87 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 35.37
Target Low Price 37.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 38.35
Open 35.40 Free Cashflow -171627744 State CA
Dividend Yield 0.00 % Return On Assets -0.0725 Time Zone Short Name EST
Trailing Eps -2.44 Day Low 35.00 Address1 2855 Gazelle Court
Shares Outstanding 157 M Price Hint 2 Target High Price 77.05
Website https://www.ionispharma.com 52 Week Change -0.2743 Average Volume 1 M
Forward Eps -3.74 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 823.80 % Is_sp_500 False Regular Market Day High 36.41
Profit Margins -44.68 % Debt To Equity 301.12 Fifty Two Week High 54.44
Day High 36.41 Shares Short 11 M Regular Market Open 35.40
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 6.44
Revenue Growth -7.20 % Shares Percent Shares Out 0.0700 Operating Cashflow -351943008
Currency USD Time Zone Full Name America/New_York Market Cap 5 B
Is_nasdaq_100 False Zip 92010 Quote Type EQUITY
Industry Biotechnology Long Name Ionis Pharmaceuticals, Inc. Regular Market Day Low 35.00
Held Percent Institutions 1.02 Current Price 35.90 Enterprise To Ebitda -15.38
Financial Currency USD Current Ratio 8.91 Gross Margins -14.31 %
Industry Disp Biotechnology Number Of Analyst Opinions 25 Country United States
Float Shares 156 M Two Hundred Day Average 42.60 Ir Website http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-irhome
Enterprise Value 5 B Price To Sales Trailing12 Months 7.06 Forward PE -13.96
Regular Market Volume 923689 Ebitda -336270016 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.

The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.

In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2.

It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics.

The company was incorporated in 1989 and is based in Carlsbad, California.